Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1492 • ACR Convergence 2024
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Edward Vital¹, Richard Furie², Eric Morand³, Ian Bruce⁴, Jacob Knagenhjelm⁵ and Catharina Lindholm⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ²Northwell Health, Manhasset, NY, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1525 • ACR Convergence 2024
Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies
Alexandre Matar¹ and Omer Pamuk², ¹MetroHealth, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder characterized by a broad range of clinical and immunological manifestations, one of which is…
Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
Abstract Number: 1683 • ACR Convergence 2024
68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis
Shuyi Yu, Zetao Ding, Haoyu Pan, Jinyi Qian, Zhixia Yang, Xiaohan Wei, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: To evaluate the feasibility of using fibroblast activating protein inhibitor (FAPI) PET imaging as a molecular tracer and non-invasive tool for assessing renal tubulointerstitial…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 1795 • ACR Convergence 2024
Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Ting Wang¹, Runa Kuley², Payton Hermanson², Gundula Min-oo³, Natasha Crellin⁴, Ching Shang³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Gilead Sciences, Foster City, CA, ⁴Gilead, Foster City, CA
Background/Purpose: Neutrophil activation has been implicated to contribute to the systemic lupus erythematosus (SLE) pathogenesis. However, factors and mechanisms promoting neutrophil activation in SLE have…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 2159 • ACR Convergence 2024
Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
Katherine Carpenter¹, Melissa French², Sara Johnson³, Janet Johnson³, Ashley Holden⁴, Joy Buie¹, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³ProChange Behavior Solutions, South Kingstown, RI, ⁴Lupus Foundation of America, Bossier City, LA

Background/Purpose: As part of a 5-year cooperative agreement with the Centers for Disease Control and Prevention, The Lupus Foundation of America (LFA) has implemented the…
Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Angela Hu¹, Lauren Erdman², Dennisse Bonilla³, Qixuan Li³, Laura Patricia Whittall Garcia³, Dafna Gladman⁴ and Zahi Touma⁵, ¹University of British Columbia, Vancouver, BC, Canada, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…
Abstract Number: 2398 • ACR Convergence 2024
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
wen zeng¹, Yuanyuan zeng¹, Lan Zhang², Cheng Zhao¹, Fang Qin¹, Leting Zheng², Mu Huang² and ling lei¹, ¹The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic), ²The First Affiliated Hospital of Guangxi Medical University, nanning, Guangxi, China (People's Republic)
Background/Purpose: To identify whether serum 25-Hydroxyvitamin D (25(OH)D) level in first-trimester(before13 weeks of gestation) maternal is associated with pregnancy outcomes in patients with systemic lupus…
Abstract Number: 2417 • ACR Convergence 2024
Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
Romina Nieto¹, Lucia Hernandez², Marina Scolnik³, Gisela Constanza Subils⁴, Veronica Saurit⁵, Verónica Gabriela Savio⁶, Valeria Arturi⁷, Boris Kisluk⁸, Luciana González Lucero⁹, Wilfredo Patiño Grageda¹⁰, María De Los Ángeles Gargiulo¹¹, ODIRLEI MONTICIELO¹², Angela Duarte¹³, Eduardo Borba¹⁴, Luciana Parente¹⁴, Edgard Reis Neto¹⁵, Oscar Neira¹⁶, Gustavo Aroca Martínez¹⁷, Antonio Iglesias Gamarra¹⁸, Paul Méndez-Patarroyo¹⁹, Rafael López²⁰, Margarita Portela Hernandez²¹, Carlos Núñez-Álvarez²², Yelitza González Bello²³, Jorge Isaac Velasco Santos²⁴, Jorge Esquivel-Valerio²⁵, Marcos Vázquez²⁶, Maria Teresa Martinez de Filartiga²⁷, Magaly Alva Linares²⁸, Roberto Muñoz Louis²⁹, Carina Pizzarossa³⁰, Ana Carolina Ralle³¹, María Camila Riascos³², Joaquín Martínez Serventi³³, Graciela Alarcon³⁴, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁵, and Grupo Latinoamericano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Córdoba, Argentina, ⁵hospital privado universitario de cordoba, Córdoba, Argentina, ⁶Sección de Reumatología, Hospital Córdoba, Córdoba, Argentina, ⁷Hospital HIGA San Martín, La Plata, Argentina, ⁸Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, ¹⁰Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹¹Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹³Universidad Federal de Pernambuco, Pernambuco, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, ¹⁶Hospital del Salvador, Santiago de Chile, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Clínica de La Costa - Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, ²¹Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ²²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²³Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosí, Mexico, ²⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, ²⁷Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁸Servicio de Reumatologia. Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, ²⁹Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ³⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ³¹Hospital Señor del Milagro, Salta, Argentina, ³²Centro de Referencia en Osteoporosis & Reumatología, Cali, Colombia, ³³Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, ³⁴The University of Alabama at Birmingham, Oakland, CA, ³⁵Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with complex multi-systemic involvement. Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus…
Abstract Number: 2434 • ACR Convergence 2024
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Nicole Narayan¹, Joshua Hoffman², Claire Langrish¹, Sibel Ucpinar³, Pedro Corpuz³, Barbara Mittleman⁴ and Mera Tilley², ¹Alumis, South San Francisco, CA, ²Alumis Inc, South San Francisco, CA, ³Alumis, South San Francisco, ⁴Alumis, Inc., San Francisco, CA
Background/Purpose: ESK-001 is a potent, highly selective, oral, allosteric small molecule inhibitor of TYK2 currently being investigated in adults with active SLE in the LUMUS…
Abstract Number: 2580 • ACR Convergence 2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Eduardo Mysler¹, Stanislav Ignatenko², Alexander Gordienko³, Josefina Cortés-Hernández⁴, Nancy Agmon-Levin⁵, Pongthorn Narongroeknawin⁶, Katarzyna Romanowska-Prochnicka⁷, Nan Shen⁸, Hana Ciferská⁹, Masanari Kodera¹⁰, James Cheng-Chung Wei¹¹, Piotr Leszczynski¹², Joung Liang Lan¹³, Rafał Wojciechowski¹⁴, Tunde Tarr¹⁵, Elena Vishneva¹⁶, Yi-Hsing Chen¹⁷, Yuko Kaneko¹⁸, Stephanie Finzel¹⁹, Alberta Hoi²⁰, Masato Okada²¹, Ajchara Koolvisoot²², Shin-Seok Lee²³, Lie Dai²⁴, Hiroshi Kaneko²⁵, Bernadette Rojkovich²⁶, Lingyun Sun²⁷, Eugeny Zotkin²⁸, Jean-François Viallard²⁹, Berta Paula Magallares³⁰, Tirtha Sengupta³¹, Carole Sips³², Carole Lau³³, Alexandre Avrameas³² and Stephen J Oliver³⁴, ¹Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ²Charité Research Organisation, GmbH, Berlin, DE, Berlin, Germany, ³SM Kirov Military Medical Academy, St Petersburg, RU, St Petersburg, Russia, ⁴Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ⁵Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, IL, Tel Aviv, Israel, ⁶Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, TH, Bankok, Thailand, ⁷Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, PL, Warsaw, Poland, ⁸Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, CZ, Prague, Czech Republic, ¹⁰Department of Dermatology, Japan Community Healthcare Organization, Chukyo Hospital, Nagoya, JP, Nagoya, Japan, ¹¹Department of Rheumatology, Chung Shan Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹²Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznan, Poland, ¹³Rheumatology and Immunology Center, China Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁴Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, ¹⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, HU, Debrecen, Hungary, ¹⁶LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, ¹⁷Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, ²⁰Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ²¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, JP, Tokyo, Japan, ²²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, Bangkok, Thailand, ²³Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea, ²⁴Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, Guangzhou, China (People's Republic), ²⁵Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, JP, Tokyo, Japan, ²⁶Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, HU, Budapest, Hungary, ²⁷Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ²⁸V A Nasonova Research Institute of Rheumatology, Moscow, RU, Moscow, Russia, ²⁹CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ³⁰Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, ³¹Novartis Pharma India, Hyderabad, IN, Hyderabad, India, ³²Novartis Pharma AG, Basel, CH, Basel, Switzerland, ³³Novartis Pharma, East Hanover, NJ, USA, East Hanover, ³⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736) is an afucosylated, fully human IgG1 monoclonal antibody with a dual mechanism of action of enhanced B-cell depletion through antibody-dependent cellular cytotoxicity…
Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Joy Park¹, Lanlan Ji¹, Jorge Cabezas¹, Xiaojing Wang², Bryan Blaker¹, Dilip Rao¹, Aparna Godavarthy¹, Lucero Blaker¹, FNU Ruchi¹, Ioana Coman¹, Nancy Olsen³, Joshua Lewis², Mariko Ishimori⁴, Kyriakos Kirou⁵, Christina Donath¹, Sara Kahlown⁶, Damira Sereda¹, Marlene Marte Furment¹, Sandy Nasr⁷, Sravani Lokineni¹, rosalind Ramsey-Goldman⁸, Michael Weisman⁹, Arthur Weinstein¹⁰, Cynthia Aranow¹¹, Banki Katalin¹², Michael McDermott¹³, Daniel Wallace¹⁴ and Andras Perl¹, ¹SUNY, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Penn State University/Milton S Hershey, Hershey, PA, ⁴Cedars-Sinai Health System, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ⁷SUNY Upstate University Hospital, syracuse, NY, ⁸Northwestern University, Chicago, IL, ⁹Stanford University, Los Angeles, CA, ¹⁰Georgetown University, Pasadena, CA, ¹¹Feinstein Institutes for Medical Research, New York, NY, ¹²SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ¹³University of Rochester, Rochester, NY, ¹⁴Cedars Sinai, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].